![Ascelia Pharma: Wrap up from interview with Deputy CEO Julia Waras Brogren](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/d0b8bfb9-a57e-4d79-b406-f0df775b2e0a.png)
Ascelia Pharma
8.7 SEK +3.57%HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement. See disclaimer.
Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital. Ascelia Pharma is listed on Nasdaq Small Cap Stockholm with ticker ACE.
Read moreLatest research
Analyst
![Henrik Ekman Henrik Ekman](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://content.inderes.se/assets/6e03ef5d-f5bb-4113-a20b-1a7d036027c4.png)
![Claus Thestrup Claus Thestrup](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://content.inderes.se/assets/637ef734-dcbf-426c-bf91-0ac4a79aa71e.png)
Latest videos
Financial calendar
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Sunstone life Science Ventures Fund II K/S | 13.7 % | 14.1 % |
Avanza Pension | 8.2 % | 8.4 % |
Premium
This content is for our Premium customers only.
![Ascelia Pharma: Wrap up from interview with Deputy CEO Julia Waras Brogren](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/d0b8bfb9-a57e-4d79-b406-f0df775b2e0a.png)
![Ascelia Pharma - Commercial and partnership strategy](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/d0b8bfb9-a57e-4d79-b406-f0df775b2e0a.png)
Ascelia Pharma - Commercial and partnership strategy
![Ascelia Pharma: Podcast interview with CEO Magnus Corfitzen and CSO Andreas Norlin - Strong Orviglance data](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/d0b8bfb9-a57e-4d79-b406-f0df775b2e0a.png)
Ascelia Pharma: Podcast interview with CEO Magnus Corfitzen and CSO Andreas Norlin - Strong Orviglance data
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
![HCA Capital: Wrap up from 2024 Life Science seminar](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/ab49c0b1-56d0-4e1c-b729-6c79c89b7be2.png)
HCA Capital: Wrap up from 2024 Life Science seminar
![Life Science seminar 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/ab49c0b1-56d0-4e1c-b729-6c79c89b7be2.png)
Life Science seminar 2024
![Ascelia Pharma (One-pager): The market is still only partly discounting likelihood of approval and successful launch of Orviglance](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/d0b8bfb9-a57e-4d79-b406-f0df775b2e0a.png)
Ascelia Pharma (One-pager): The market is still only partly discounting likelihood of approval and successful launch of Orviglance
![Ascelia Pharma: Wrap up from interview Deputy CEO Julie W. Brogren](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/f269375c-f73d-444e-a01a-b723dcaa8498.png)
Ascelia Pharma: Wrap up from interview Deputy CEO Julie W. Brogren
![Ascelia Pharma - What happened during Q1?](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/d0b8bfb9-a57e-4d79-b406-f0df775b2e0a.png)
Ascelia Pharma - What happened during Q1?
Redeye: Ascelia Pharma - Time for take-off
Penser Access by Carnegie: Ascelia Pharma: Med positiva data i ryggen
![Ascelia Pharma, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/23e41dac-2efc-4b4e-90b9-3a7dd80ad442.png)
Ascelia Pharma, Audiocast with teleconference, Q1, 2024
Kvartalsrapport Q1: Primärt effektmått uppnått med starka headline-resultat i fas 3-studien med Orviglance
Quarterly Report Q1: Primary Endpoint Met with Strong Headline Results in Orviglance Phase 3 Study
Penser Access by Carnegie: Ascelia Pharma: Medvind i seglen
Välkommen till Ascelia Pharma uppdatering till investerare: Att föra Orviglance till patienterna
Welcome to Ascelia Pharma Investor Update: Bringing Orviglance to Patients
Bulletin from the Annual General Meeting in Ascelia Pharma AB on 6 May 2024
Kommuniké från årsstämma den 6 maj 2024 i Ascelia Pharma AB
![Ascelia Pharma: Reaches most important milestone in company history](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/cd9fabe8-37f9-489a-8b5a-20380428cc50.png)